HopeStage
Back to all studies
CompletedNCT00300963

Talnetant, risperidone, or placebo for psychosis in schizophrenia

About this titleRead the official source — NCT00300963

This study evaluated the safety and effectiveness of Talnetant for people with schizophrenia.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Talnetant for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 19 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2004
Recruitment status
Completed
Enrollment listed in the registry
275
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00300963
Official title
Show the full official title

A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Anaheim · Cerritos

17 more locations
  • Garden Grove
  • Glendale
  • National City
  • Oceanside
  • Pico Rivera
  • Rosemead
  • San Diego
  • Upland
  • Washington D.C.
  • North Miami
  • Atlanta
  • St Louis
  • Clementon
  • Philadelphia
  • Austin
  • Irving
  • Richmond

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Talnetant for people with schizophrenia.

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including Talnetant.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies